All In Biotech

Drug Trial Radar · NCT00006392

S0000 Selenium and Vitamin E in Preventing Prostate Cancer

Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Nov 20, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 35,533 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

35,533

Actual

Start

Jul 2001

Primary completion

May 2011

Study completion Sep 2012

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Male only, from 50 years, up to 120 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of selenium and vitamin E, either alone or together, in preventing prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • Vitamin EDrug

    400 IU daily by mouth for 7-12 years

  • SeleniumDrug

    200 mcg daily for 7-12 years

  • Vitamin E placeboOther

    daily for 7-12 years

  • selenium placeboOther

    daily for 7-12 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Prostate CancerTime frame: Every six months for 7 to 12 years depending on when the participant was randomized.

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University

    Chicago, Illinois

  • Midwest Center for Hematology/Oncology

    Joliet, Illinois

  • Cardinal Bernardin Cancer Center at Loyola University Medical Center

    Maywood, Illinois

  • CCOP - Cancer Research for the Ozarks

    Springfield, Missouri

  • St. John's Regional Health Center

    Springfield, Missouri

  • Good Samaritan Hospital Cancer Treatment Center

    Cincinnati, Ohio

  • Bethesda North Hospital

    Cincinnati, Ohio

  • Tod Children's Hospital

    Youngstown, Ohio

  • LaFortune Cancer Center at St. John Medical Center

    Tulsa, Oklahoma

  • Geisinger Medical Center

    Danville, Pennsylvania

  • Geisinger Medical Group - Scenery Park

    State College, Pennsylvania

  • Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center

    Wilkes-Barre, Pennsylvania

  • U.T. Cancer Institute at University of Tennessee Medical Center

    Knoxville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.